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Abstract RhoA/B/C and CDC42/Rac, which form two sub-
groups of the rho guanosine triphosphatase (GTPase) family,
regulate various aspects of actin cytoskeleton organisation. In
cytosol, guanosine diphosphate (GDP) dissociation inhibitor
(GDI) interacts with and maintains rho GTPases in their inactive
GDP-bound form. RhoGDI is a ubiquitously expressed GDI,
whereas D4/LyGDI is hematopoietic cell-specific and 10-fold
less potent than RhoGDI in binding to and regulating rho
GTPases. We have combined microanalytical liquid chromatog-
raphy with the use of specific antibodies in order to separate D4/
LyGDI and RhoDGI-complexes from the cytosol of U937 cells
and to demonstrate that the two GDIs associate with different
rho protein partners. RhoGDI can form a complex with
CDC42Hs, RhoA, Rac1 and Rac2, while none of these GTPases
was found to interact with D4/LyGDI. In addition, we found that
stimulation of U937 cells with phorbol ester leads to phospho-
rylation of D4/LyGDI. Our results suggest that LyGDI forms
complexes with specific rho GTPases expressed in hematopoietic
cells where it may regulate specific pathways.
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1. Introduction
Rho guanosine triphosphatases (GTPases), which form a
distinct branch of the Ras-like low molecular weight GTP-
binding protein superfamily, are involved in actin cytoskele-
ton organization [1]. Even though the precise biochemical
mechanisms of their function remain largely elusive, several
e¡ector molecules that bind to the GTP-bound form of Rho
GTPases and mediate their regulatory activity on the actino-
myosin system have been recently identi¢ed (for review see
[2]). Indeed, and as for the other members of the Ras super-
family, rho GTPases switch between an inactive guanosine
diphosphate (GDP)-bound state and an active GTP-bound
state. Much e¡ort has been put into identifying and character-
izing regulators of this GDP/GTP cycle. Guanine nucleotide
exchange factors promote the exchange of GTP for GDP.
GTPase-activating proteins (GAP) catalyze GTP hydrolysis,
which returns the protein to the inactive conformation. An-
other class of regulators appears to prevent GDP dissociation.
RhoGDI (GDP Dissociation Inhibitor) was ¢rst identi¢ed in
bovine brain cytosol on the basis of its ability to inhibit GDP
dissociation from RhoA [3]. Later on it was found that
RhoGDI could also complex other Rho family members in-
cluding CDC42Hs [4] and Rac1/2 [5^7] and that geranylger-
anylation of the C-terminal CAAX motif of rho partners was
required for these interactions [8]. In addition, RhoGDI sol-
ubilizes the GDP-bound form of rho proteins from mem-
branes [9] and may also control their translocation from the
cytosol to the target membrane [10].
Recently a second GDI has been discovered that shares
67% amino acid identity with RhoGDI [11^13]. In contrast
to RhoGDI which is ubiquitous, this novel protein is almost
exclusively expressed in the hematopoietic lineages and has
been called LyGDI [11] or D4 [12]. Although recombinant
D4/LyGDI (the nomenclature adopted throughout this paper)
binds to and inhibits GDP dissociation from puri¢ed
CDC42Hs, RhoA and Rac in vitro, it appears at least 10-
fold less potent than RhoGDI in doing so [11,14]. Cerione’s
group has provided an explanation for this reduced e⁄ciency:
the a⁄nity of D4/LyGDI for CDC42Hs is 15-fold lower than
the a⁄nity of RhoGDI for CDC42Hs [15]. Therefore the
question remains whether D4/LyGDI is an actual regulator
of these rho proteins in cells of the hematopoietic lineage
where both inhibitors should coexist.
In order to assess the substrate speci¢city of RhoGDI and
D4/LyGDI in U937, a human myelomonocytic cell line, we
developed a chromatographic fractionation procedure allow-
ing the separation of complexes containing either RhoGDI or
D4/LyGDI. The distribution of RhoA, CDC42Hs, Rac1 and
Rac2 in the di¡erent fractions enriched for RhoGDI or D4/
LyGDI was determined using speci¢c antibodies. In addition,
the e¡ect of activation of U937 cells by phorbol 12-myristate
13-acetate (PMA) on the phosphorylation of D4/LyGDI and
RhoGDI was determined.
2. Materials and methods
2.1. Cells, antibodies and reagents
U937 cells (ATCC CRL 1593) were maintained in RPMI-1640
(Gibco BRL) supplemented with 10% fetal calf serum (FCS). Activa-
tion with phorbol 12-myristate 13-acetate (PMA, Sigma) was per-
formed at a concentration of 100 ng/ml. The polyclonal serum against
D4/LyGDI was raised against the N-terminal peptide (MTEKA-
PEPHVEEDDDDELDSK, position 1^21 in the human D4/LyGDI
protein [11,12]) conjugated to keyhole-limpet haemocyanin (Calbio-
chem) with glutaraldehyde (Sigma). A sample of 1 mg of the conju-
gated peptide was homogenized in Freund’s complete adjuvant (DIF-
CO Laboratories) by vortexing and injected subcutaneously into
rabbits. The rabbits were boosted at 2-week intervals with 0.5 mg
of conjugated peptide in Freund’s incomplete adjuvant (DIFCO Lab-
oratories). The polyclonal antibody raised against CDC42Hs internal
peptide has been described [16]. The anti-RhoGDI and anti-Rac2
antibodies were purchased from Santa Cruz. Mouse mAbs speci¢c
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for RhoA or Rac1 have been raised against the recombinant proteins
(T. Azuma, unpublished). [35S]Methionine/cysteine (TRAN35S-LA-
BEL1) was obtained from ICN Pharmaceuticals Inc.
[32P]Orthophosphate was purchased from Amersham. Unless indi-
cated, chemicals were purchased from Sigma.
2.2. Immunoprecipitation of metabolically labeled proteins
For metabolic labeling of phosphorylated proteins, cells were ¢rst
incubated for 2 h in phosphate-free RPMI-1640 (Gibco BRL) with
10% FCS which had been dialyzed for 15 h against Tris-bu¡ered
saline (TBS: 150 mM NaCl, 50 mM Tris-HCl, pH 7.4). Then cells
were labeled for 3 h in 0.5 mCi/ml of [32P]orthophosphate in phos-
phate-free medium (107 cells/ml). To activate the cells, PMA was
added to a concentration of 100 ng/ml and cells were further incu-
bated for 15 min. For [35S]methionine/cysteine labeling, cells were
incubated for 2 h in methionine/cysteine-free RPMI-1640 (Gibco
BRL) supplemented with 10% dialyzed FCS and then labeled for 3 h
in 0.25 mCi/ml TRAN35S-LABEL1 in methionine/cysteine-free me-
dium (107 cells/ml). After labeling, cells were solubilized in 0.5 ml of
0.5% NP-40, 150 mM NaCl, 1 mM EDTA, 50 mM Tris-HCl, pH 7.4,
containing 1 mM PMSF, 0.1 mM VO33 and 10 mM KF. Solubilized
samples were added to antibodies (0.1 ml antiserum) which had been
pre-coupled to Protein A^Sepharose beads (0.05 ml, Pharmacia) and
mixed at 4‡C for 2 h. Immunoprecipitates were washed 3 times in
solubilization bu¡er.
2.3. Cytosol preparation
Cytosol was prepared from 109 cells grown in a spinner as already
described [17]. Brie£y, cells were homogenized in 250 mM sucrose,
3 mM imidazole, pH 6.8, 10 Wg/ml antipain, 1 Wg/ml leupeptin, 1 mM
PMSF. The homogenate was centrifuged for 10 min at 1000Ug and
the post-nuclear supernatant (PNS) was collected. The PNS was cen-
trifuged at 100 000Ug for 30 min. The supernatant (20 mg/ml of
protein) corresponding to the cytosolic extract, was aliquoted and
stored in liquid nitrogen. Cytosol from PMA-di¡erentiated U937 cells
was prepared from 108 cells cultured in the presence of 100 ng/ml
PMA for 5 days in 175 cm2 plastic £asks. U937 cells that adhered
to plastic upon di¡erentiation were scraped with a rubber policeman
and cytosol was prepared as described above except that the homog-
enization bu¡er was supplemented with 0.1 mM VO33 and 10 mM
KF.
2.4. Chromatographic separation of complexed RhoGDI and
D4/LyGDI
Separation of complexes was performed by a combination of ion
exchange chromatography (Mono Q PC 1.6/5, Pharmacia, Uppsala,
Sweden) followed by size exclusion chromatography (Superdex 75 PC
3.2/30, Pharmacia, Uppsala, Sweden) using the microanalytical liquid
chromatography SMART system (Pharmacia, Uppsala, Sweden). Cy-
tosol was prepared as described above. Four mg of protein in 500 Wl
of 250 mM sucrose, 3 mM imidazole, pH 6.8, was loaded onto a
Mono Q column. The £ow rate was 50 Wl/min. Elution of proteins
from the column was induced by applying a NaCl gradient in 250 mM
sucrose, 3 mM imidazole, pH 6.8, starting from 0 up to 0.4 M NaCl in
42 min. The fraction size corresponded to 100 Wl. After chromatog-
raphy, 50 Wl of fractions 8 or 11 were adjusted to 0.3 M NaCl in 250
mM sucrose, 3 mM imidazole, pH 6.8 and loaded onto a Superdex 75
column equilibrated in the same bu¡er. The £ow rate was 40 Wl/min
and the fraction size 50 Wl. Calibration of the Superdex 75 column was
performed with chicken albumin (45 kDa, peak fraction: 16) and
chymotrypsin (25 kDa, peak fraction: 20). After separation, fractions
were analyzed by SDS-gel electrophoresis and Western blotting.
2.5. Electrophoresis and Western blotting
SDS-PAGE was carried out according to the system of Laemmli
[18] using 12% gels. Gels with 35S-labeled proteins were treated with
Enhance (Dupont-NEN). For two-dimensional gel electrophoresis,
samples (50 Wg cytosolic protein) were run on IEF tube gels, with a
linear pH gradient between pH 4.5 and 7.4 and then on 12% acryl-
amide second dimension resolving gels as described [19]. The resolved
proteins were electroblotted onto nitrocellulose and detected with
speci¢c antibodies. Detection of bound antibodies was performed us-
ing goat anti-rabbit or anti-mouse peroxidase-conjugated antibodies
(Sigma) with the enhanced chemiluminescence system (ECL, Amer-
sham).
3. Results and discussion
The comparison of the amino acid sequence of RhoGDI
[20] and D4/LyGDI [11,12] revealed that the two proteins
are highly homologous except for the N-terminal region
(not shown). Therefore, we raised a D4/LyGDI N-terminal
antiserum directed against a synthetic peptide corresponding
to residues 1 to 21 of human D4/LyGDI. D4/LyGDI could be
speci¢cally detected as a V28-kDa species in cytosolic ex-
tracts from human U937 myelomonocytic cells by our N-ter-
minal antiserum, while it was absent in HeLa cell cytosol (Fig.
1A). In contrast, the V29-kDa RhoGDI was present in both
cell lines. These results are in agreement with previous reports
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Fig. 1. PMA activation of myelomonocytic U937 cells induces the phosphorylation of D4/LyGDI. A: The D4/LyGDI N-terminal antiserum is
speci¢c, as shown by Western blotting analysis of HeLa (lanes 1 and 3) or U937 (lanes 2 and 4) cell extracts. Lanes 1, 2, D4/LyGDI N-termi-
nal antiserum; lanes 3, 4, anti-RhoGDI antibodies. B: Immunoprecipitation from detergent extracts prepared from 35S-labeled U937 cells (lanes
1, 2) or [32P]orthophosphate labeled U937 cells (lanes 3^6). After labeling as described in Section 2, cells were incubated for 15 min in the ab-
sence (lanes 3, 4) or in the presence of PMA (100 ng/ml) (lanes 5, 6). Immunoprecipitations were performed with D4/LyGDI N-terminal antise-
rum (lanes 1, 3 and 5) or anti-RhoGDI antibodies (lanes 2, 4 and 6). Molecular weight markers are indicated (kDa).
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showing that RhoGDI is ubiquitously expressed whereas D4/
LyGDI expression is restricted to hematopoietic cells [11,12]
in which both factors coexist (this study).
D4/LyGDI is phosphorylated upon T cell activation by
phorbol ester [11] and RhoGDI appears to be constitutively
phosphorylated in bovine neutrophils [21]. We thus investi-
gated the phosphorylation of RhoGDI and D4/LyGDI in
PMA-stimulated U937 cells. Both GDIs could be immunopre-
cipitated from 35S metabolically labelled U937 cells using spe-
ci¢c antibodies (Fig. 1B, lanes 1^2), but only D4/LyGDI was
immunoprecipitated as a phosphorylated protein from 32P-la-
belled U937 cell extracts in response to PMA treatment (Fig.
1B, lanes 3^6). Next, we characterized the kinetics of D4/
LyGDI phosphorylation in PMA-stimulated U937 cells.
U937 cells were incubated for various periods of time in the
presence of PMA, cytosolic extracts were prepared and ana-
lyzed by two-dimensional gel electrophoresis followed by
Western blotting with anti-D4/LyGDI or anti-RhoGDI anti-
bodies. Prior to stimulation, a single spot was detected using
anti-D4/LyGDI antibodies (Fig. 2A). Several spots of lower
pI values were detected in response to PMA and very likely
corresponded to di¡erent phosphorylated forms (Fig. 2A).
Phosphorylation of D4/LyGDI was detected after 5 min of
PMA treatment and persisted for at least 1 h in the presence
of the phorbol ester. In the same conditions, RhoGDI was
detected as a unique spot (Fig. 2B). Since phosphorylated
RhoGDI has already been reported as multiple spots that
could be resolved by IEF [21], our data show that RhoGDI
is not phosphorylated in U937 cells upon phorbol ester acti-
vation in contrast to D4/LyGDI.
We next addressed the substrate speci¢city of these two
GDIs vs. di¡erent Rho GTPases. Conditions were ¢rst set
up in order to separate cytosolic complexes containing RhoG-
DI or D4/LyGDI. Cytosols prepared from U937 cells were
applied onto a Mono Q column and after extensive washing,
bound proteins were eluted by increasing salt concentration.
Analysis of the column fractions by SDS-PAGE followed by
immunoblotting with speci¢c antibodies showed that both
GDIs could be separated into fractions enriched for RhoGDI
(peaking between fractions 6^11, V120^150 mM NaCl, Fig.
3A) or D4/LyGDI (peaking between fractions 10^13, V150^
200 mM NaCl, Fig. 3B).
In order to identify the GTPases complexed with RhoGDI
or D4/LyGDI in U937 cell cytosol, the fractions eluted from
the Mono Q column were analyzed for the presence of various
rho proteins by immunoblotting using speci¢c antibodies. As
shown in Fig. 3C, CDC42Hs peaked in fractions 7^8 eluted
from the Mono Q column. In addition, anti-CDC42Hs anti-
bodies gave a weak but reproducible signal in fractions 16 and
17 of the eluate. Rac1 and RhoA were detected using speci¢c
mouse mAbs. Rac1 was most abundant in fractions 6^8 of the
eluate (Fig. 3D), while RhoA was present in fractions 8 and 9
(Fig. 3E). Finally, since the hematopoietic-speci¢c Rac2
GTPase is expressed at very low level in resting U937 cells
but can be induced upon di¡erentiation in the presence of
PMA ([22] and data not shown), cytosol from di¡erentiated
U937 cells that had been incubated for ¢ve days in the pres-
ence of PMA were applied onto the Mono Q column. As
shown in Fig. 3F, speci¢c antibodies detected the Rac2
GTPase in fractions 8^9 of the eluate (the positions of RhoG-
DI and D4/LyGDI in the Mono Q fractions from PMA-dif-
ferentiated cell extracts were unchanged as compared to un-
treated cells, data not shown). Several observations support
the conclusion that RhoGDI and Rho proteins that coeluted
from the MonoQ column were in stochiometric complexes.
First and as shown in Fig. 4, when Mono Q fractions 8
(peak of RhoGDI) or 11 (peak of D4/LyGDI) were applied
on a Superdex 75 gel ¢ltration column, the GDIs eluted as a
single peak in fraction 16 of the sizing column with an appar-
ent molecular mass of 45^50 kDa (see Section 2). In contrast,
recombinant D4/LyGDI, N-terminally tagged with six histi-
dine residues, eluted with an apparent mass of 20^25 kDa
from the Superdex 75 column (data not shown). These results
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Fig. 3. CDC42Hs, RhoA, Rac1 and Rac2 are complexed with
RhoGDI in U937 cell cytosol. U937 cell cytosol was chromato-
graphed on a Mono Q anion-exchange column as in Section 2.
Fractions were analyzed by SDS-PAGE and Western blotting with
speci¢c antibodies against RhoGDI (A), D4/LyGDI (B), CDC42Hs
(C), Rac1 (D), RhoA (E) or Rac2 (F). Rac2 distribution was ana-
lyzed from cytosol extracts prepared from PMA-di¡erentiated U937
cells. The position of RhoGDI and D4/LyGDI eluted from the
Mono Q column was identical in cytosol from untreated or PMA-
di¡erentiated cells (not shown).
Fig. 2. Kinetics of phosphorylation of D4/LyGDI in U937 cells in
response to PMA. Cytosolic extracts were prepared from U937 cells
after 0, 5, 10 or 60 min of incubation in the presence of PMA and
were resolved by two-dimensional gel electrophoresis. After electro-
transfer D4/LyGDI (panel A) or RhoGDI (panel B) were identi¢ed
by Western blotting with speci¢c antibodies. Only the sections of
2D gels corresponding to the area where the GDIs migrate are
shown. The position of a 28.6-kDa molecular weight marker is indi-
cated.
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indicate that the GDIs that were separated on the MonoQ
column were associated with Rho proteins in heterodimeric
complexes with an apparent mass of about 45^50 kDa. In
addition, when U937 cytosol was directly applied onto the
Superdex 75 column, both RhoGDI and D4/LyGDI were ex-
clusively eluted with an apparent molecular mass of 45^50
kDa, indicating that the GDIs were entirely complexed with
rho GTPases in U937 cytosol (data not shown). Finally, the
di¡erences in the predicted isoelectric points of RhoA
(pI = 5.9), CDC42Hs (pI = 6.5), Rac1 (pI = 8.53), Rac2
(pI = 7.56) and RhoGDI (pI = 4.96) or D4/LyGDI (pI = 4.85)
[13,23] make it very unlikely that RhoGDI and these four
distinct rho proteins could be eluted from the Mono Q col-
umn at similar salt concentrations unless they were separated
as heterodimeric complexes.
Altogether, these results demonstrate that CDC42Hs, Rac1,
RhoA and Rac2 are speci¢cally associated with the ubiquitous
RhoGDI in U937 cell cytosol, while D4/LyGDI is complexed
with distinct rho GTPase(s).
An important conclusion drawn from this study is that two
related GDIs which are coexpressed in U937 cells, the ubiq-
uitous RhoGDI and the hematopoietic-speci¢c D4/LyGDI,
are found in the cytosol as heterodimeric complexes involving
di¡erent rho GTPases. Since its discovery by Takai’s group,
various studies have reported the association of RhoGDI with
CDC42Hs, RhoA, Rac1 and Rac2 [3^7]. D4/LyGDI was ini-
tially identi¢ed as a hematopoietic cell-speci¢c gene product,
homologous to RhoGDI and acting as an inhibitor of GDP
dissociation from RhoA [11]. Later on, it was found that D4/
LyGDI is less e⁄cient by a factor of 10^20 than RhoGDI in
its ability to inhibit GDP/GTP exchange or to promote mem-
brane release of CDC42Hs (as well as RhoA and Rac1) [14].
The regions of RhoGDI and D4/LyGDI that are responsible
for the di¡erence in substrate speci¢city have been mapped to
the carboxyl terminal residues 172^180 of RhoGDI and par-
ticularly Ile-177 (Asn-174 of D4/LyGDI) [24]. Recently, No-
manbhoy and Cerione using a £uorescence spectroscopic as-
say have determined the binding a⁄nity of the RhoGDI/
CDC42Hs complex (KdV30 nM) which appears to be 15-
fold higher than the binding of D4/LyGDI to CDC42Hs
(KdV440 nM) [15]. Therefore, although it is possible to ob-
serve a weak a⁄nity and inhibitory activity of D4/LyGDI for
RhoA, CDC42Hs or Rac1/2 in vitro, our study clearly dem-
onstrates that D4/LyGDI is not able to form stable complexes
with these rho GTPases in vivo and is associated with as yet
uncharacterized rho proteins.
Two new GTPases belonging to the Rho subgroup have
recently been identi¢ed: TTF [25] and RhoE [26]. They share
unusual structural features as compared to the classical Rho
GTPases we found complexed with RhoGDI. In the TTF
protein, the conserved Gly-12 is replaced by a serine residue
(Ser-13 of TTF), while RhoE contains three amino acid di¡er-
ences at position 17 (Gly to Ser), 64 (Ala to Ser) and 66 (Gln
to Ser). Mutations at the corresponding positions (12, 59 and
61) confer oncogenicity to Ras [27] and, as expected, totally
abolish both intrinsic and GAP-stimulated GTP hydrolysis by
RhoE which is maintained in the GTP-bound form [26].
Whether TTF and/or RhoE form complexes with a GDI,
and more speci¢cally D4/LyGDI, could not be addressed
due to the lack of speci¢c antibodies. The observation that
RhoGDI binds equally well to the GDP- and GTP-bound
form of CDC42Hs [15] suggests that TTF and RhoE,
although they are probably locked in the active conformation,
should also be able to interact with GDI. Interestingly, TTF is
expressed in a restricted manner in hematopoietic cells [25]
and represents a potential interacting partner of D4/LyGDI
(we have observed that D4/LyGDI can solubilize overex-
pressed TTF from membranes; Dallery, E. and Chavrier, P.,
unpublished data).
Another observation concerns the rapid and speci¢c phos-
phorylation of D4/LyGDI in response to PMA treatment of
U937 cells, in contrast to RhoGDI which remains unphos-
phorylated. In bovine neutrophils, phosphorylation/dephos-
phorylation events have been implicated in the regulation of
the dissociation of the RhoA/RhoGDI complex [21]. In addi-
tion, phosphorylation has also been shown to regulate
p55RabGDI interaction with its rab protein partners [28].
So far, we have not been able to correlate the PMA-induced
phosphorylation of D4/LyGDI with a modulation of its asso-
ciation with rho proteins. By gel ¢ltration analysis, phos-
phorylated D4/LyGDI is eluted with an apparent molecular
mass of 45^50 kDa and so behaves as the unphosphorylated
molecule (data not shown). It has been postulated that GDI
may serve as a chaperone-like molecule to transport rho pro-
teins through the cytosol to their site of function at a target
membrane [29]. Phosphorylation of D4/LyGDI could be in-
volved in the regulation of this chaperone function by favor-
ing the recruitment of D4/LyGDI complexes to the mem-
brane. Concomitant to Rho translocation, free D4/LyGDI
would be released (as shown for the Rac/RhoGDI complex
[10]) and rapidly dephosphorylated, returning to the cytosol
to interact with inactivated Rho. Interestingly, exposure of
U937 cells to PMA induces their di¡erentiation from non-
adherent myelomonocytic cells to adherent macrophage-like
cells. Rho GTPases have been implicated in the regulation
of adhesion in several systems including U937 cells [30^33].
The rapid and sustained phosphorylation of D4/LyGDI upon
PMA treatment may be related to the increased adhesion of
U937 cells upon di¡erentiation.
Altogether, these results suggest that LyGDI may be in-
volved in the regulation of hematopoietic-speci¢c rho
GTPases and are possibly engaged in biochemical pathways
restricted to the hematopoietic lineage. The chromatographic
procedure developed in the present study should facilitate the
puri¢cation of D4/LyGDI-containing complexes and we hope
it will lead to the identi¢cation of its rho GTPase partners.
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Fig. 4. GDIs eluted from the Mono Q column are complexed with
Rho GTPases. Peak fractions eluted from the Mono Q column con-
taining RhoGDI (fraction 8) or D4/LyGDI (fraction 11) were chro-
matographed on Superdex 75 column and fractions were analyzed
for RhoGDI or D4/LyGDI by Western blotting. Both GDIs were
eluted in fraction 16 with an apparent molecular mass of 45^50
kDa. Fraction 20 corresponds to proteins eluted with a molecular
mass of 25^30 kDa.
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